BR112013006861A2 - ligante para ser utilizado em um sistema de liberação de fármaco, composto compreendendo um ligante, uso de um composto, sistema de liberação controlada e método para preparar um sistema de liberação controlada - Google Patents
ligante para ser utilizado em um sistema de liberação de fármaco, composto compreendendo um ligante, uso de um composto, sistema de liberação controlada e método para preparar um sistema de liberação controladaInfo
- Publication number
- BR112013006861A2 BR112013006861A2 BR112013006861A BR112013006861A BR112013006861A2 BR 112013006861 A2 BR112013006861 A2 BR 112013006861A2 BR 112013006861 A BR112013006861 A BR 112013006861A BR 112013006861 A BR112013006861 A BR 112013006861A BR 112013006861 A2 BR112013006861 A2 BR 112013006861A2
- Authority
- BR
- Brazil
- Prior art keywords
- release system
- binder
- controlled release
- compound
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38473010P | 2010-09-21 | 2010-09-21 | |
PCT/NL2011/050509 WO2012039602A1 (en) | 2010-09-21 | 2011-07-14 | Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013006861A2 true BR112013006861A2 (pt) | 2019-07-02 |
Family
ID=44630016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013006861A BR112013006861A2 (pt) | 2010-09-21 | 2011-07-14 | ligante para ser utilizado em um sistema de liberação de fármaco, composto compreendendo um ligante, uso de um composto, sistema de liberação controlada e método para preparar um sistema de liberação controlada |
Country Status (9)
Country | Link |
---|---|
US (1) | US9339554B2 (pt) |
EP (1) | EP2618845B1 (pt) |
JP (2) | JP5934221B2 (pt) |
KR (1) | KR101961961B1 (pt) |
CN (1) | CN103209710B (pt) |
BR (1) | BR112013006861A2 (pt) |
CA (1) | CA2811869A1 (pt) |
ES (1) | ES2776983T3 (pt) |
WO (1) | WO2012039602A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2389960B1 (en) | 2006-06-15 | 2018-02-28 | MicroVention, Inc. | Environmentally responsive hydrogel |
US8470035B2 (en) | 2007-12-21 | 2013-06-25 | Microvention, Inc. | Hydrogel filaments for biomedical uses |
US10639396B2 (en) | 2015-06-11 | 2020-05-05 | Microvention, Inc. | Polymers |
US9456823B2 (en) | 2011-04-18 | 2016-10-04 | Terumo Corporation | Embolic devices |
EP2723388B1 (en) | 2011-06-27 | 2021-04-14 | Cristal Delivery B.V. | Controlled release system |
WO2014142653A1 (en) | 2013-03-11 | 2014-09-18 | Cristal Delivery B.V. | Vaccination composition |
CN110433326A (zh) * | 2014-04-29 | 2019-11-12 | 微仙美国有限公司 | 包含活性剂的聚合物 |
JP2017537298A (ja) | 2014-10-03 | 2017-12-14 | サンウェル・エンジニアリング・カンパニー・リミテッド | 略一定の温度を維持するための熱シールド |
JP7029957B2 (ja) | 2014-10-03 | 2022-03-04 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | インタクトな細菌由来のベシクルへの低分子化合物の充填の向上 |
SG10201913945QA (en) | 2015-06-04 | 2020-03-30 | Crititech Inc | Taxane particles and their use |
EP3377047A1 (en) | 2015-11-20 | 2018-09-26 | Cristal Delivery B.V. | Nanoparticles with active targeting |
JP6970683B2 (ja) | 2016-04-04 | 2021-11-24 | クリティテック・インコーポレイテッド | 固形腫瘍治療のための方法 |
WO2018172546A1 (en) | 2017-03-24 | 2018-09-27 | Rigontec Gmbh | Method for designing rig-i ligands |
WO2018227037A1 (en) | 2017-06-09 | 2018-12-13 | Crititech, Inc. | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
US10398646B2 (en) | 2017-06-14 | 2019-09-03 | Crititech, Inc. | Methods for treating lung disorders |
BR112020005814A2 (pt) | 2017-10-03 | 2020-09-24 | Crititech, Inc. | administração local de partículas antineoplásicas em combinação com administração sistêmica de agentes imunoterapêuticos para o tratamento de câncer |
CN111615405B (zh) * | 2017-11-17 | 2023-11-28 | 国家科学研究中心 | 聚合物前药及其皮下和/或肌内给药 |
KR20210032422A (ko) | 2018-07-13 | 2021-03-24 | 크리스탈 딜리버리 비.브이. | 티오사이클로헵틴 유도체들 및 이들의 용도 |
EP3990635A1 (en) | 2019-06-27 | 2022-05-04 | Rigontec GmbH | Design method for optimized rig-i ligands |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2496275A (en) * | 1945-08-17 | 1950-02-07 | Eastman Kodak Co | Polymers and copolymers of unsaturated amides |
US3220986A (en) * | 1960-12-27 | 1965-11-30 | Union Carbide Corp | 2-vinyloxyethyl sulfide compounds and polymerization products thereof |
GR64493B (en) * | 1976-07-06 | 1980-03-31 | Huels Chemische Werke Ag | Method for the preparation of methalylo-sulfonic natrium |
IT1174496B (it) * | 1984-02-17 | 1987-07-01 | Nuovo Consor Sanitar Nazionale | Composti ad attivita'ipolipemizzante |
FR2687400A1 (fr) * | 1992-02-17 | 1993-08-20 | Atochem Elf Sa | Nouveaux composes (meth)acryliques, leur procede de preparation et leur application a la synthese de nouveaux polymeres. |
US5935599A (en) * | 1996-10-28 | 1999-08-10 | The Board Of Trustees Of The University Of Illinois | Polymer-associated liposomes for drug delivery and method of manufacturing the same |
BR9807030B1 (pt) * | 1997-01-28 | 2009-01-13 | agente tensoativo polimerizÁvel, e, soluÇço aquosa de tensoativo. | |
EP1072617A1 (en) | 1999-07-30 | 2001-01-31 | Universiteit van Utrecht | Temperature sensitive polymers |
US7425581B2 (en) | 1999-07-30 | 2008-09-16 | Universiteit Utrecht | Temperature sensitive polymers |
KR20080030564A (ko) * | 2005-05-12 | 2008-04-04 | 태피스트리 파마슈티컬스 인코퍼레이티드 | 표적 컨쥬게이트에 적합한 분자 구조물 |
JP5622117B2 (ja) * | 2008-07-21 | 2014-11-12 | ポリテリクスリミテッド | 生体分子を接合するための新規な試薬及び方法 |
BRPI0913704A2 (pt) | 2008-09-18 | 2017-06-20 | Univ Utrecht Holding Bv | método para a preparação de um sistema de liberação controlada |
-
2011
- 2011-07-14 CA CA2811869A patent/CA2811869A1/en not_active Abandoned
- 2011-07-14 BR BR112013006861A patent/BR112013006861A2/pt not_active IP Right Cessation
- 2011-07-14 ES ES11741699T patent/ES2776983T3/es active Active
- 2011-07-14 WO PCT/NL2011/050509 patent/WO2012039602A1/en active Application Filing
- 2011-07-14 CN CN201180045535.5A patent/CN103209710B/zh not_active Expired - Fee Related
- 2011-07-14 US US13/825,036 patent/US9339554B2/en not_active Expired - Fee Related
- 2011-07-14 EP EP11741699.0A patent/EP2618845B1/en active Active
- 2011-07-14 KR KR1020137009155A patent/KR101961961B1/ko active IP Right Grant
- 2011-07-14 JP JP2013529089A patent/JP5934221B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-06 JP JP2016093069A patent/JP6144383B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20130136991A (ko) | 2013-12-13 |
KR101961961B1 (ko) | 2019-03-25 |
WO2012039602A1 (en) | 2012-03-29 |
CA2811869A1 (en) | 2012-03-29 |
US20130261094A1 (en) | 2013-10-03 |
JP5934221B2 (ja) | 2016-06-15 |
CN103209710A (zh) | 2013-07-17 |
EP2618845A1 (en) | 2013-07-31 |
JP2016145250A (ja) | 2016-08-12 |
EP2618845B1 (en) | 2020-02-26 |
JP2013537224A (ja) | 2013-09-30 |
US9339554B2 (en) | 2016-05-17 |
CN103209710B (zh) | 2016-04-06 |
JP6144383B2 (ja) | 2017-06-07 |
ES2776983T3 (es) | 2020-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013006861A2 (pt) | ligante para ser utilizado em um sistema de liberação de fármaco, composto compreendendo um ligante, uso de um composto, sistema de liberação controlada e método para preparar um sistema de liberação controlada | |
UY33890A (es) | Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa | |
ECSP11011183A (es) | Compuestos orgánicos | |
ECSP11011184A (es) | Compuestos orgánicos | |
CR11801A (es) | Derivados de indazol sustituidos con fenilo y benzodioxinilo | |
GT201200334A (es) | Morfolinopirimidinas y su uso en terapia | |
UY33485A (es) | Derivados de acido(2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos. | |
CO6640285A2 (es) | 5-alquinil-pirimidinas | |
ECSP10010695A (es) | Compuestos de piridina | |
UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
RS53890B1 (en) | STABILIZED POLYMER DELIVERY SYSTEM | |
UY30824A1 (es) | Nuevos derivados de idazolil éster o amida, composiciones farmacéuticas conteniéndolas, procesos de preparacion y aplicaciones. | |
UY30195A1 (es) | Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones | |
UY31774A (es) | Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
BR112013006341A2 (pt) | formulações agrícolas líquidas com estabilidade aperfeiçoada | |
CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
BR112012029647A2 (pt) | novos derivados de pirimidinas | |
BR112014018617A8 (pt) | Polímero catiônico com base em glicogênio,complexo entre um polímero catiônico com base em glicogênio e um composto aniônico, composição farmacêutica, e, uso de um complexo | |
BR112013016770A2 (pt) | formulação farmacêutica, fármaco biofarmacêutico, seringa ou caneta pré-preenchida, uso de uma formulação farmacêutica | |
UY31645A1 (es) | Nuevas imidazolidinas fenil-sustituidas, procedimiento para su preparación, medicamentos que conprenden dichos compuestos y su uso. | |
ECSP11010786A (es) | 5-alquinil-pirimidinas | |
BR112017013260A2 (pt) | composição de catalisador para a cura de resinas contendo grupos de epóxi | |
BR112015024971A2 (pt) | derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk | |
CL2010001432A1 (es) | Compuestos derivados de 2-oxo-alquil-1-piperazin-2-ona, afines por los receptores p75ntr; procedimiento para preparar los compuestos; compuesto intermediario; medicamento y composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2628 DE 18-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |